Mastocytosis is a disorder resulting from an abnormal mast cell (MC) accumulation in tissues that is often associated with the D816V mutation in KIT, the tyrosine kinase receptor for stem cell factor. Therapies available to treat aggressive presentations of mastocytosis are limited, thus exploration of novel pharmacological targets that reduce MC burden is desirable. Since increased generation of the lipid mediator sphingosine-1-phosphate (S1P) by sphingosine kinase (SPHK) has been linked to oncogenesis, we studied the involvement of the two SPHK isoforms (SPHK1 and SPHK2) in the regulation of neoplastic human MC growth. While SPHK2 inhibition prevented entry into the cell cycle in normal and neoplastic human MCs with minimal effect on cell survival, SPHK1 inhibition caused cell cycle arrest in G2/M and apoptosis, particularly in D816V-KIT MCs. This was mediated via activation of the DNA damage response (DDR) cascade, including phosphorylation of the checkpoint kinase 2 (CHK2), CHK2-mediated M-phase inducer phosphatase 3 depletion, and p53 activation. Combination treatment of SPHK inhibitors with KIT inhibitors showed greater growth inhibition of D816V-KIT MCs than either inhibitor alone. Furthermore, inhibition of SPHK isoforms reduced the number of malignant bone marrow MCs from patients with mastocytosis and the growth of D816V-KIT MCs in a xenograft mouse model. Our results reveal a role for SPHK isoforms in the regulation of growth and survival in normal and neoplastic MCs and suggest a regulatory function for SPHK1 in the DDR in MCs with KIT mutations. The findings also suggest that targeting the SPHK/S1P axis may provide an alternative to tyrosine kinase inhibitors, alone or in combination, for the treatment of aggressive mastocytosis and other hematological malignancies associated with the D816V-KIT mutation.
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inTrODUcTiOn Sphingosine-1-phosphate (S1P) is a lipid mediator with multiple biological functions. Evidence indicates that S1P plays a significant role in cancer as it promotes cell migration and cell proliferation, prevents cell death, and induces angiogenesis (1, 2) . S1P is generated in cells in response to growth factors, cytokines, and other extracellular stimuli through the activation of two isoforms of sphingosine kinase (SPHK1 and SPHK2) (3) (4) (5) . Upregulated expression of SPHK, particularly SPHK1, and increased levels of S1P have been linked with poor cancer prognosis and resistance to cytotoxic therapy agents in malignant cells from solid tumors, lymphomas, and leukemias (1, (6) (7) (8) . Selective targeting of either SPHK1 or SPHK2 can effectively inhibit malignant cell growth in culture and in xenograft models and the preferential effect of one isoform over the other appears to be cell type specific (1, (9) (10) (11) (12) (13) (14) (15) . Nevertheless, an inhibitor of SPHK2, ABC294640, is in early clinical trials for patients with pancreatic cancer and diffuse large B cell lymphomas (clinical trials NCT01488513 and NCT02229981) (16) . In addition, safingol, which inhibits SPHK1 and SPHK2, has been used in combination with cisplatin in Phase I clinical trials (clinical trial NCT00084812) for the treatment of locally advanced or metastatic solid tumors (17) .
Abnormal mast cell (MC) proliferation and accumulation in various tissues occurs in mastocytosis, which in its more aggressive forms can be life-threatening (18, 19) . This increased MC burden in systemic mastocytosis (SM) is most often associated with the presence of an activating mutation in the catalytic domain of KIT, the receptor for stem cell factor, that causes ligand-independent activation of KIT and downstream signaling, especially within the MC compartment (20) (21) (22) . Thus, targeting KIT activity has been a focus of pharmacological strategies to treat aggressive SM, with the limitation that the extended tyrosine kinase conformation of D816V-KIT is not inhibited by tyrosine kinase inhibitors such as imatinib (21, 23) . In addition, midostaurin (PKC412), which effectively blocks D816V-KIT activity (24) and the growth of MC expressing D816V-KIT (25) , has time-limited effects on improvement of clinically relevant responses in patients with aggressive SM (26) . Thus, new strategies that target critical growth signaling pathways in neoplastic MCs are needed.
Mast cells of murine or human origin express both SPHK1 and SPHK2 isoforms, which are activated following IgE receptor stimulation, and S1P consequently generated plays a critical role in IgE-mediated release of mediators and cytokines (27) (28) (29) (30) (31) . In addition, receptors that are important for maturation/growth/ survival of MCs such as KIT and the IL-3 receptor also stimulate SPHKs (27) . However, it has not been studied whether SPHK and S1P regulate MC growth and survival.
Here, we show that SPHK1 and SPHK2 are upregulated in neoplastic human MCs and are important regulators of their proliferation and survival in culture. Inhibition of SPHK2 reduces the growth of primary mouse and human mast cells (HuMCs) cultures and neoplastic human MC lines by slowing their entry into the cell cycle. On the other hand, SPHK1 inhibition induces cell cycle arrest followed by cell death in neoplastic MCs expressing D816V-KIT but not in normal MCs. We demonstrate that this effect is mediated by a previously unrecognized regulation of the checkpoint kinases CHK1 and CHK2 and the activation of the DNA damage response (DDR) cascade. Inhibition of SPHKs also reduces the number of malignant MCs from bone marrow of mastocytosis patients ex vivo and in a preclinical mouse model of tumor xenografts using a MC line with D816V-KIT. Our results show promise for clinical investigation of this non-tyrosine kinase-based approach to the treatment of aggressive SM and other hematological malignancies with D816V-KIT.
MaTerials anD MeThODs reagents
Reagents were obtained as follows: anti-rabbit IgG 800CW and anti-mouse IgG 680 RD from Licor Biosciences (Lincoln, NE, USA); goat anti-rabbit IgG-AF488 from Abcam (Cambridge, MA, USA); and anti-CD117-BV605, anti-FcεRI-BV421, and anti-CD25-BV711 from Biolegend (San Diego, CA, USA). Antibodies against phospho-AKT(Ser473), BCL-2-associated X protein (BAX), B-cell lymphoma (BCL2), cleaved caspase 2 (CASP2), caspase 3 (CASP3), cleaved CASP3, M-phase inducer phosphatase 3 (CDC25c), cyclin-dependent kinase 1 (CDK1), phospho-CHK2(Thr68), phospho-ERK(Thr202/Tyr204), p38, phospho-p38(Thr180/Tyr182), and p53 were from Cell Signaling Technology (Danvers, MA, USA); anti-CASP2 and anti-CHK2 were from Millipore (Billerica, MA, USA); anti-CHK1, antiphospho-CHK1(Ser345), hIL-6, and hSCF were from R&D Systems (Minneapolis, MN, USA); anti-phospho-p53(Ser20) (human) and anti-GADD45 were from Santa Cruz (Santa Cruz, CA, USA); anti-H2A histone family member X (H2AX) and anti-phospho-H2AX (Ser130) were from Abclonal (Woburn, MA, USA); anti-SPHK1 was from ECM Biosciences (Versailles, KY, USA), anti-SPHK2 was from MyBioSource (San Diego, CA, USA); anti-CD34-APC and anti-AKT were from BD Biosciences (San Jose, CA, USA); anti-ERK and anti-SPHK2 (used for IHC) were from Thermo Fisher Scientific (Waltham, MA, USA); anti β-actin and anti-SPHK1 (used for IHC) were from Sigma Aldrich (St. Louis, MO, USA); mouse IL-3 and SCF were from Peprotech Inc. (Rocky Hill, NJ, USA); the SPHK1 inhibitor SKI-178 was from Millipore and the SPHK2 inhibitor ABC294640 was from MedKoo Biosciences (Morrisville, NC, USA).
human samples, cell cultures, and cell lysates
CD34
+ peripheral blood progenitors from human blood and bone marrow aspirates from patients with SM were obtained following informed consent under protocols approved by the NIAID Institutional Review Board (98-I-0027 and 02-I-0277). The characteristics of these patients are specified in Table S1 in Supplementary Material. Primary HuMC cultures were derived from CD34
+ progenitors as described (32, 33) ; and mononuclear cells from marrow aspirates were separated in a Ficoll gradient and cultured for 5 days in StemPro media supplemented with 100 ng/mL SCF (34 Sphk2-deficient, and WT mice were cultured as described (28, 35, 36) . P815 mastocytoma murine cells with a mutation homologous to the human D816V mutation were from ATCC (Manassas, VA, USA). HCT116 cells with or without the D816V-KIT introduced by CRISPR were from Thermo Fisher Scientific. P815 and HCT116 cells were cultured as specified by the respective providers. Cell lysates for Western blots were prepared from 1 × 10 6 cells and processed as described (37 Determination of cell growth cell cycle analysis LAD2 or HMC-1 cells (1 × 10 6 ) were plated at 0.5 × 10 6 cells/mL in 6-well plates and cultured with the SPHK inhibitors or vehicle for 3 days. Cells were then harvested and fixed in 70% ethanol at 4°C for 2 h. After washing twice with PBS, cells were stained with PI/RNase Staining Buffer (BD Pharmingen) and analyzed on a LSR II (BD Biosciences) flow cytometer for PI positive signal (Emission at 605 nm). Single cells were gated and PI signal visualized using histogram plots. Distribution of cells containing DNA characteristic G0-G1, S, and G2/M cell cycle phases was determined using FlowJo as described (38) .
cell Death/apoptosis analysis
The annexin V FITC Apoptosis Detection Kit II (BD Pharmingen) was used following the manufacturer's protocol. Cells (1 × 10 6 cells/mL) were incubated with vehicle or the SPHK inhibitors for 3 days and stained with FITC-annexin V for 30 min in the dark on ice. After washing, 7-amino-actinomycin D (7-AAD), which binds DNA with high affinity but is excluded by intact cells, was added to differentiate early apoptosis from late apoptosis or other forms of cell death, and cells were analyzed by flow cytometry (LSR II BD). The percentage of early apoptotic cells was determined as the frequency of annexin V positive/7-AAD negative cells, while the percentage of all dead cells was determined as the frequency of the 7-AAD positive population (annexin V positive and negative).
expression of cell cycle genes by Quantitative Pcr arrays Total RNA was isolated from HMC-1.2 cells (3 × 10 6 ) treated with vehicle or SPHK inhibitors for 24 h. RNA was converted into cDNA using the RT 2 First-Strand Kit (Qiagen), and then used as a template to perform a quantitative RT 2 Profiler PCR Array for Human Cell Cycle (Qiagen PAHS-020Z) to analyze the expression levels of 84 genes involved in regulation of cell cycle. The raw threshold cycle data were analyzed using SA Biosciences web-based tool, 1 as instructed by the manufacturer. An ingenuity pathway analysis (IPA) program (Mountain View, CA, USA) was employed for pathway analysis using the fold changes between the SPHK1-I-or SPHK2-I-treated cells compared with vehicletreated cells. Changes in expression of cyclin genes were confirmed by using specific TaqMan gene expression assays (Thermo Fisher Scientific). 
sphingolipid analysis
Lipids were extracted from 8 × 10 6 HMC-1.2 cells following treatment with SPHK1-I (10 µM) or SPHK2-I (50 µM) for 16 h. Ceramides, sphingosine, and S1P were measured by HPLCtandem MS by the Lipidomics Core at the Medical University of South Carolina on a Thermo Finnigan (Waltham, MA, USA) TSQ 7000 triple quadrupole mass spectrometer, operating in a multiple reaction-monitoring positive ionization mode as described (39) . The sphingolipid concentration was normalized using inorganic phosphate measurements of the lipid extracts.
Mice and Xenograft Model
All studies involving mice were performed in accordance with NIH guidelines and with the animal study proposal (LAD2E) approved by the NIH/NIAID Animal Care and Use Committee. WT, Sphk1-, and Sphk2-null mice were generated as described (40) , and bred within NIAID animal facilities.
For the xenograft tumor model, NSG mice (NOD-scid IL2R γ null ) from Jackson laboratories (Bar Harbor, ME, USA) (6-8 weeks) were injected subcutaneously with 1 × 10 6 HMC-1. 
statistical analysis
Statistical significance was determined using Student's t-test.
Comparison of changes over time between different groups was performed using two-way ANOVA using Prism software. A p value of less than 0.05 was considered significant. Data are shown as mean ± SEM unless specified otherwise.
resUlTs sPhKs regulate the growth of normal Murine and human Mcs
To investigate the role of SPHKs on MC proliferation, we first compared the growth rates of MCs derived from Sphk1-and Sphk2-deficient bone marrow progenitors (BMMC) to normal BMMCs. As shown in Figure 1A , growth rates of Sphk-deficient cells were significantly reduced compared with WT BMMCs. Treatment WT-BMMCs with small molecule inhibitors specific for SPHK1 ; referred here as SPHK1-I] or SPHK2 [ABC294640 (12, 43) ; referred in here as SPHK2-I] exhibited similar effects on growth rates as BMMCs genetically deficient in Sphk1 or Sphk2 ( Figure 1B) . We then explored the effect of these inhibitors on the proliferation/survival of 6-week cultures of CD34
+ -derived HuMCs containing more than 85% KIT + / FcεRI + double-positive MCs. While SPHK1-I did not show any significant effect, treatment with SPHK2-I markedly reduced HuMC numbers in cultures from three different healthy donors ( Figure 1C) . The data support a role for SPHKs in the growth/ survival of normal human and mouse MCs, although the relative involvement of SPHK1 appears to differ between human and mouse by mechanisms unrelated to the relative expression of SPHK1 since SPHK1 is more abundant in human than in mouse MCs (28) .
sPhKs are Upregulated in neoplastic Mcs
Enhanced SPHK expression in a number of malignant cell types has been associated with increased proliferation, cancer prognosis, and clinicopathological parameters of disease (1, 44) . Similarly, we found an increase in the expression of SPHK1 and SPHK2 in mastocytosis MC lines (i.e., LAD2 and HMC-1) compared with normal HuMCs (Figure 2A ; Figure S1 in Supplementary Material), which was variable depending on the donor. Of note, expression and activity of SPHK2 in normal HuMCs albeit much lower than in neoplastic cells were on the average higher than that for SPHK1 (28) .
Although SPHKs are predominantly cytosolic enzymes (45), both SPHK1 and SPHK2 (46, 47) can be abundantly expressed in the nucleus of cancer cell lines such as MCF7, COS7, and HeLa cells and a higher nuclear expression of SPHK1 has been associated with significantly shorter survival in breast cancer patients (44) . Using IHC for SPHK1 and SPHK2, we observed that SPHK1 and SPHK2 were distributed homogeneously throughout the cell in normal HuMCs, and more concentrated in perinuclear areas and the plasma membrane ( Figure S1 in Supplementary Material). Analysis of the confocal IHC images confirmed the increased overall cellular expression of SPHKs in neoplastic MCs and a higher density of SPHK, particularly SPHK1, in the nucleus of neoplastic MCs compared with normal HuMCs ( Figure S1 in Supplementary Material). This was especially apparent in HMC-1.2 cells. However, the percentage of nuclear SPHK (respect to the total cellular content) was similar among the cell types suggesting that the enrichment of nuclear SPHK was the result of higher overall expression but not of a differential distribution pattern in neoplastic cells.
sPhK1 is critical for the growth/survival of cells With D816V-KiT
We then examined whether the growth of neoplastic MCs was influenced by SPHK1-I or SPHK2-I as we found in normal MCs. While treatment with SPHK2-I resulted in a 40-50% reduction in the number of both LAD2 ( Figure 2B ) and HMC-1 cells (Figures 2C,D) , the effect of SPHK1-I differed depending on the MC line. Similar to normal HuMCs cultures (Figure 1C ), SPHK1-I had only a modest inhibitory effect in the growth of LAD2 MCs ( Figure 2B) . However, unlike LAD2 cells, the growth of HMC-1.1 and HMC-1.2 cells carrying oncogenic KIT mutations was markedly reduced by 60% (Figures 2C,D) . Furthermore, HMC-1.2 MCs, harboring the D816V-KIT mutation in addition to the G560V-KIT present in HMC-1.1, were significantly more sensitive to lower concentrations of SPHK1-I than HMC-1.1 cells (compare Figures 2C,D) . This contrasted with the lack of effects of SPHK1-I on the growth of normal HuMCs (Figure 1C) , although the effects varied slightly in the different donors, potentially reflecting, to some extent, differences in SPHK expression.
Of note, SPHK1 and 2 inhibitors were more effective at reducing the expansion of HMC-1.2 cells than 300 nM PKC412 or 2 µM dasatinib ( Figure 2E) , which are known to inhibit D816V-KIT. Combination treatment with dasatinib or PKC412 and SPHK inhibitors showed higher inhibition than either inhibitor alone, although the combination with PKC412 was not statistically different compared to SPHK inhibitors alone ( Figure 2E) .
We also examined whether other cells carrying D816V-KIT also had higher sensitivity to SPHK1-I. The growth of the mastocytoma MC line P815 containing the murine equivalent to human D816V-KIT was also remarkably inhibited by SPHK1-I compared with normal BMMC ( Figure S2A in Supplementary Material). Furthermore, the colon cancer epithelial cell line HCT116 was susceptible, as most cancer cells are, to growth inhibition by either SPHK1-I or SPHK2-I, but they were even more susceptible earlier on to the effects of the SPHK1-I when a mutation in D816V-KIT was additionally introduced ( Figure S2B in Supplementary Material). The finding of a higher susceptibility of cells carrying D816V-KIT to SPHK1-I is of interest given that patients with these mutations are less responsive to KIT inhibitor treatments.
Differential effects of sPhK1 and sPhK2 inhibition on cell cycle arrest and survival of neoplastic Mcs
We next explored how SPHK1-I and SPHK2-I affected cell growth of neoplastic MCs, focusing on HMC-1.2 since these cells have the D816V mutation commonly found in SM. In HMC-1.2, inhibition of SPHK1 caused a prominent cell cycle arrest in G2/M ( Figure 3A) accompanied by extensive apoptosis evidenced by annexin V + staining (Figure 3B) , while in contrast inhibition of SPHK2 resulted in the accumulation of cells in the G0/G1 phases and reduction of the percentage of cells in the S phase ( Figure 3A) with no major effects on cell death ( Figure 3B ). G2/M arrest and apoptosis induced by SPHK1-I were significantly more prominent in HMC-1.2 than in HMC-1.1 and LAD2 cells (Figure 3C ), in agreement with their overall effects on cell numbers. SPHK2-I, however, prevented the exit from G1 into the S phase in a comparable manner in all neoplastic MCs (Figure 3D) , consistent with its similar effects reducing cell numbers in all the cell lines. Treatment of HMC-1.2 with either of these inhibitors did not significantly affect the expression of SPHK1 or SPHK2 (data not shown).
Subsequent studies on the mechanisms by which these inhibitors regulate growth and survival were mostly performed in neoplastic MCs with D816V-KIT, i.e., HMC-1.2, because of the clinical relevance of this mutation and its resistance to most tyrosine kinase inhibitors.
effect of sPhK1 and sPhK2 inhibitors on sphingolipid Metabolites
As expected, inhibition of SPHK1 or SPHK2 caused substantial reductions in the cellular concentration of S1P, the product of In panels (c-e), Cyquant cell proliferation assay was used to assess growth inhibition, and data are represented as mean ± SEM of three independent experiments each performed in triplicate. The number of cells at the end of the experiment in untreated controls was considered 100%. Horizontal dotted lines represent the number of cells originally plated (as a percentage of the cell count at day 3 in untreated cultures). Significant differences from untreated and treated pairs are shown thus; *p < 0.05, **p < 0.01, ***p < 0.001. . In panels (a-D), the values are the mean ± SEM of three separate experiments. Significant differences from untreated and treated pairs are shown thus; *p < 0.05, **p < 0.01, ***p < 0.001. these lipid enzymes ( Figure 4A) . The reduction in S1P was particularly notable with SPHK2-I treatment ( Figure 4A ) and was accompanied by some accumulation of the substrate, sphingosine ( Figure 4B ). Since sphingosine can be converted into ceramide and, in contrast to S1P, ceramide is a sphingolipid metabolite that mediates pro-apoptotic and anti-growth effects (7, 48), we thus examined whether cell death induced by SPHK1-I could be related to increases in ceramide levels. However, increases in ceramides at the indicated times were only significantly detected in cells treated with SPHK2-I ( Figure 4C) and therefore, the distinct apoptosis induced by SPHK1-I does not seem to implicate ceramide production. Thus, both inhibitors reduced S1P levels in these cells but only SPHK2-I resulted in detectable increases in ceramides that could contribute to SPHK2-I-mediated growth inhibition, albeit not substantially to apoptosis.
sPhK1-i and sPhK2-i Differentially affect the expression of genes regulating the DDr and repair Pathways
To gain insights into the mechanisms of growth inhibition and induction of apoptosis in HMC-1.2 cells by SPHK1-I, we investigated the effects of these inhibitors on the expression of 84 genes that are critical for cell cycle regulation using a qPCR array. The original datasets with the changes in gene expression induced by SPHK1 or SPHK2 inhibitors can be found in NCBI's Gene Expression Omnibus (49) and are accessible through 2 Profiler PCR Array. Fold changes in the genes induced by either inhibitor were then analyzed using the ingenuity pathway analysis (IPA) with 1.5-fold as a cutoff. Shown is a comparison analysis done by IPA of the canonical pathways most significantly affected by either inhibitor and sorted by the activation Z score (blue: predicted inhibited and red: predicted activated). In bold, pathways related to DNA damage response cascade. GEO Series accession number GSE111060. 2 Treatment of HMC-1.2 cells with either SPHK1-I or SPHK2-I reduced cyclin E (CCNE1) mRNA expression, a cyclin responsible for late G1 or G1/S transition. Expression of cyclins A and B, which facilitate progression into the S and G2 phases (50), was also reduced by the inhibitors although more significantly so by SPHK2-I ( Figure 5A) . Analysis of the expression of all cell cycle-related genes in the array with the IPA software predicted a downregulation of "S phase entry" and increased "G1/S and G2/M checkpoint regulation" as Canonical Pathways regulated by both SPHK1-I and SPHK2-I ( Figure 5B ; Table S2 in Supplementary Material) . Surprisingly, these results suggest that both inhibitors similarly restrict progression into S phase and imply that the accumulation in G2/M observed only after SPHK1-I treatment occurs by mechanisms other than a specific downregulation of cyclins regulating transitions into G2 or mitosis.
As shown in Figure 5B and Table S2 in Supplementary Material, analysis by IPA of all cell cycle genes affected by the inhibitors gave further insights into these potential mechanisms. IPA suggested that pathways related to DDR mechanisms (noted in bold in Figure 5B ) were distinctly regulated by these inhibitors. As pathways involved in the DDR are key in coordinating cell cycle progression with DNA repair and cell death/survival decisions, this analysis raised the possibility that arrest on G2/M by SPHK1-I treatment could be the result of unrepairable DNA damage or incomplete replication instead of regulation of cyclin expression. 
cells
We next investigated whether the DDR-related pathways were indeed affected by inhibition of SPHK1 in HMC-1.2 cells and which of the possible DDR cascades were involved. DNA damage is sensed by the PI3K-like kinases ataxia telangiectasia and Rad3-related protein (ATR) and ataxia telangiectasia mutated (ATM). ATR and ATM phosphorylate CHK1 and CHK2, respectively, which coordinate signaling cascades leading to cell cycle arrest and DNA repair or induce cell death or senescence if the damage cannot be repaired (51) (52) (53) (Figure 6A) . While no significant effect on CHK1 or CHK2 phosphorylation was observed in cells treated with SPHK2-I, treatment with SPHK1-I markedly increased the phosphorylation of CHK2 in Thr68 (Figure 6B ; Figure S3 in Supplementary Material), a site phosphorylated by ATM, suggesting an activation of ATM in response to doublestranded breaks or telomere damage (54, 55) . Consistent with this conclusion, HMC-1.2 cells treated with SPHK1-I showed increased phosphorylation of H2AX at Ser139 an early marker of double-stranded breaks. By contrast, SPHK1-I did not affect the phosphorylation in Ser345 of CHK1 but reduced CHK1 expression, indicating a unique activation of the DDR in HMC-1.2 cells, with CHK2 activation but simultaneous depletion of CHK-1, which could have catastrophic effects on cells.
Phosphorylation of CHK2 may activate an array of effectors in the DDR that orchestrates the cell outcome ( Figure 6A) . Phosphorylation of p53 at Ser20, a residue that is a substrate for CHK2, was substantially increased by SPHK1-I. Increased p53 phosphorylation, as expected, resulted in the stabilization of p53 and thus increased levels compared with untreated cells (Figure 6C ; Figure S3 in Supplementary Material). Downstream of p53 and consistently with its tumor suppressor activity, the levels of its transcriptional targets, the pro-apoptotic BAX, and the anti-apoptotic BCL2 were upregulated and downregulated, respectively. As a consequence, the executioner CASP3 was cleaved and activated. Cleaved CASP2 was also increased after treatment with SPHK1-I but not with SPHK2-I (Figure 6C ; Figure  S3 in Supplementary Material). Although CASP2 cleavage may occur via CASP3, CASP2 activation by SPHK1-I is also in agreement with the observed reduction in CHK1 levels, an effect that has been reported to limit DNA repair and induce apoptosis via CASP2 (56-58) (Figure 6A) . The results suggest that inhibition of SPHK1 causes cell death in HMC-1.2 by selectively activating the CHK2/p53/CASP3 pathway and causing CHK1 depletion with consequent CASP2 activation.
Activation of the DDR may also lead to arrest of cells in various stages of the cell cycle. Consistent with the observed cell cycle arrest in G2/M, SPHK1-I but not SPHK2-I caused a depletion of the dual-specificity phosphatase CDC25c (Figure 6D ; Figure  S3 in Supplementary Material) which removes the inhibitory phosphate residues from CDK1 and allows the cell cycle to proceed. This effect on CDC25c is likely to be a consequence of SPHK-1 induced activation of CHK2 since CHK2 was reported to mediate either ubiquitination/degradation or phosphorylation/ inactivation of CDC25c (53, 55) . In addition, CDK1 expression levels were also markedly reduced by SPHK1-I treatment. The depletion of CDK1 ensures no further progression into mitosis. Furthermore, the expression of growth arrest and DNA damageinducible (GADD45α), another transcriptional target of p53 that mediate cell cycle arrest (59), were increased in HMC-1.2 cells treated with either SPHK1-I or SPHK2-I ( Figure 6D ; Figure S3 in Supplementary Material). Overall, the data showing GADD45α upregulation supports the view that both inhibitors slow down entry into the cell cycle (G1/S) but an additional and more prominent and catastrophic consequence of SPHK1 inhibition in HMC-1.2 cells is the activation of the DDR, with CHK2-mediated G2/M arrest via CDC25c and CDK1 depletion as well as apoptotic cell death via CHK2/p53 and CHK1/CASP2 pathways.
activation of chK2 by sPhK1-i is More Prominent in cells With D816V-KiT
We then tested whether the activation of this pathway by SPHK1-I correlated with its effects on the cell cycle and apoptosis in the different cell lines. Concomitantly with the effect on G2/M arrest and apoptosis, the effect of SPHK1-I treatment on CHK2 phosphorylation and CASP3 activation was more pronounced in HMC-1.2 than in HMC-1.1 and in LAD2 cells (Figure 6E ; Figure  S4 in Supplementary Material), which lack D816V-KIT. Similarly, treatment of murine P815 cells (harboring D816V-KIT) with SPHK1-I also induced Chk2 phosphorylation, p53 stabilization, and Casp3 activation, while this pathway was not observed in normal mouse BMMCs ( Figure S5A in Supplementary Material). In addition, SPHK1-I induced a more pronounced CHK2 phosphorylation in HCT116 carrying D816V-KIT than the parental HCT116 cells ( Figure S5B in Supplementary Material). Thus, these data implicate activation of the DDR by SPHK1-I as a mechanism involved in the increased susceptibility of cells with D816V-KIT to this inhibitor.
sPhK inhibitors reduce growth of Bone Marrow neoplastic Mcs From Patients and of ectopic Mc Tumors in Mice
To further assess the potential effectiveness of these inhibitors in preclinical models, we first treated bone marrow cells from four different patients with indolent and smoldering mastocytosis (see Table S1 in Supplementary Material) with SPHK1-1 or SPHK2-I. After 5 days in culture, the number of bone marrow malignant CD25
+ MCs was substantially reduced by treatment with SPHK1-I and SPHK2-I (Figure 7A) . Similarly, these inhibitors reduced by >50% the number of CD25 + MCs in 6-week-old CD34 + -derived MC cultures from peripheral blood from one of the patients (Figure 7B) . Whereas SPHK2-I was similarly effective in reducing MC numbers from normal donors (compare Figure 7B to Figure 1C ), SPHK1-I significantly inhibited the growth of patient's CD25 + MCs but not normal donor's HuMCs (compare Figures 7B and 1C) .
We next examined whether SPHK inhibition could also reduce the growth of D816V-KIT MCs in vivo in a xenograft mouse model. HMC-1.2 cells inoculated subcutaneously into immunodeficient mice formed palpable ectopic tumors that grew steadily over the course of the experiment. Mice treated daily with SPHKI-1 (20 mg/kg) or SPHK2-I (40 mg/kg) after the tumors were palpable (50 mm 3 ) showed a significant reduction in tumor volume over time compared with those in mice treated with vehicle ( Figure 7C) . The inhibition of growth by SPHK1-I and SPHK2-I of primary neoplastic MCs from patients and of D816V-KIT MCs in vivo support the conclusion that SPHK inhibitors are appropriate candidates to consider for clinical applications in the treatment of mastocytosis.
DiscUssiOn
Advanced SM can result in aggressive neoplastic MC infiltrates in tissues and end-of-organ compromise, requiring cytoreductive therapy. Current treatments targeting oncogenic D816V-KIT have shown limited long-term improvement and thus additional therapeutic approaches are needed. In this study, we find that SPHK1 and SPHK2, the enzymes responsible for the generation of the lipid mediator S1P, are upregulated in neoplastic human MCs and critically regulate their proliferation/survival. We also demonstrate the effectiveness of inhibition of SPHK1 and SPHK2 in reducing the numbers of malignant bone marrow MCs from patients with SM and in vivo in xenograft models. Of particular interest, inhibition of SPHK1 by SKI-178 prevented entry into mitosis and induced cell death most prominently in MCs with D816V-KIT. This involved the activation of CHK2 kinase concomitant with the depletion of CHK1, and downstream induction of the DDR leading to cell death. Overall, the data presented suggest great potential for SPHK inhibitors as alternatives to tyrosine kinase inhibitors in the treatment of aggressive SM.
Sphingosine kinases, especially SPHK1, are well-recognized regulators of proliferation and survival, although their involvement in these processes depends on the cell type. We find that neoplastic human MCs with oncogenic KIT mutations (including HMC-1.2 and bone marrow CD25 + malignant MC from patients with SM) as well as other cells carrying D816V-KIT, are more vulnerable to inhibition of SPHK1 than normal MCs or other cell counterparts lacking this mutation. This suggests that SPHK1 may mediate critical oncogenic pathways of D816V-KIT and, together with findings that loss of SPHK1 reduces bioactive mediator release by human MCs (28, 29) , make SPHK1 a more desirable target for therapeutic development than SPHK2 since it blocks both proliferation and function of MCs. Nonetheless, the SPHK2-I used in this study may also represent a drug of interest in the treatment of aggressive mastocytosis since it is already in clinical trials for other malignancies and as demonstrated here, is also quite effective in reducing the numbers of CD25 + MCs and other neoplastic MCs. The finding that SPHK2-I also affects the growth of normal MCs may not detract from its use, since imatinib-induced depletion of normal MCs during imatinib therapy did not show adverse clinical manifestations (60) .
An unexpected observation in this study was the differential effects of SPHK1 compared with SPHK2 inhibition despite their similar effects in reducing cellular S1P levels. SPHK1 inhibition resulted predominantly in G2/M arrest and an induction of apoptosis that could not be explained by increased ceramide levels, while SPHK2 inhibition accumulated cells in G0/G1, slowing entry into the cell cycle. The arrest in G0/G1 by blockage of SPHK2 is relatively consistent among cells (46, 61, 62) but reports suggest that blockage of SPHK1 activity may arrest cells in G2/M or G0/G1 depending on the cell type (14, 15, 63, 64) . We found that both inhibitors similarly regulate the expression of cyclins in HMC-1.2, with a pattern consistent with a predicted arrest in G0/G1. A defining effect of SPHK1 suppression in neoplastic MCs, particularly those harboring D816V-KIT, was a deregulation of the DDR cascade which prevented entry into mitosis (G2/M arrest) of those cells that had passed the G0/G1 checkpoint, leading to them to programmed cell death. We propose this mechanism may be common to certain types of cancer cells and may partially explain the diverse effects on the cell cycle by SPHK1 blockage.
The activation of the DDR by SPHK1-I in D816V-KIT MCs was initiated by double-stranded breaks and induction of CHK2 activity. This effect has not been previously reported, but in other cancer cells, knockdown of SPHK1 and reduction in S1P levels sensitize them to DNA damage by ionizing radiation (IR) (65) or by doxorubicin (66) . In D816V-KIT MCs, activation of CHK2 by SPHK1-I mediated a depletion of CDC25c, a phosphatase needed for the removal of an inhibitory residue in CDK1 before entry into mitosis, and a downregulation in CDK1, which is needed for the induction of mitosis when complexed with cyclin B. Activated CHK2 also phosphorylated and stabilized p53, which then increased BAX but reduced BCL2 levels, resulting in cleavage and activation of the executioner CASP3. In addition to CHK2 activation, CHK1 was distinctly depleted by SPHK1-I treatment, an observation consistent with a compromise in DNA repair and activation of CASP2. Inactivation or loss of CHK1 under robust genotoxic insults or IR damage drives a type of cell death that can bypass p53 deficiency. This has been the basis for recent treatment strategies in refractory cancers that would combine DNA damage-promoting drugs with inhibitors of CHK1 (57, 67, 68) . Our data pose the intriguing possibility that SPHK1 inhibition on its own can act in D816V-KIT MCs like such proposed combination therapy (67) since it activates a CHK2-induced DDR while shutting down CHK1-induced repair, ensuring apoptosis of the transformed cells by p53-dependent and -independent mechanisms. These observations in turn suggest that synergistic treatments with anticancer drugs that cause DNA damage may prove even more effective.
The specific mechanism by which inhibition of SPHK1 by SKI-178 causes DNA double-stranded breaks is, however, unclear. The possibility that the inhibitor directly causes DNA damage is unlikely because LAD2 cells were not sensitive to this inhibitor or exhibited H2AX phosphorylation. A similar cascade of CHK2 activation, CDC25c depletion, p53 and CASP3 activation has been described after loss of telomere stability initiated by either reduced telomerase activity or alterations in the complexes that protect telomeres (55, (69) (70) (71) (72) (73) (74) . Since nuclear S1P generated by SPHKs stabilizes the catalytic subunit of telomerase (human telomerase reverse transcriptase, hTERT) (75) , an interesting possibility is that SPHK1 may become critical for the proliferation and viability of cells with oncogenic D816V-KIT by preventing double-stranded breaks at fragile sites, particularly telomeres, during oncogene-induced replication stress. SPHK1 in these cells may support hTERT activity, which is increased in HMC-1.2 compared with normal human MCs (76), or promote repair mechanisms, which are upregulated in oncogenic cells. Nevertheless, further studies are needed to identify whether these or other mechanisms are involved.
In conclusion, this study determines that SPHK activities are important regulators for the proliferation of normal and neoplastic MCs in vitro and in MCs of patients with mastocytosis ex vivo. Moreover, we show that inhibition of their activity reduces MC burden in a xenograft model of neoplastic MCs and identify SPHK1 as an efficacious target for oncogenic KIT signaling. SPHK1 inhibition triggers an apoptotic program that resembles DDR-mediated apoptosis resulting from loss of telomere stability. Although more studies are necessary to evaluate the clinical potential of these inhibitors, our data show promise targeting SPHKs as an effective therapy, perhaps in combination with existing therapies, in the treatment of aggressive mastocytosis and other diseases involving D816V-KIT mutations.
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